Current approaches in lipid-based nanocarriers for oral drug delivery
Lipid-based nanocarriers have gained much interest as carriers of drugs with poor oral bioavailability because of their remarkable advantages like low toxicity, affordable scale-up manufacture, strong biocompatibility or high drug loading efficiency. The potential of these nanocarriers lies in their...
Gespeichert in:
| Veröffentlicht in: | Drug delivery and translational research 2021-04, Vol.11 (2), p.471-497 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 497 |
|---|---|
| container_issue | 2 |
| container_start_page | 471 |
| container_title | Drug delivery and translational research |
| container_volume | 11 |
| creator | Plaza-Oliver, María Santander-Ortega, Manuel Jesús Lozano, María Victoria |
| description | Lipid-based nanocarriers have gained much interest as carriers of drugs with poor oral bioavailability because of their remarkable advantages like low toxicity, affordable scale-up manufacture, strong biocompatibility or high drug loading efficiency. The potential of these nanocarriers lies in their ability to improve the gastrointestinal stability, solubility and permeability of their cargo drugs. However, achieving efficient oral drug delivery through lipid-based nanocarriers is a challenging task, since they encounter multiple physicochemical barriers along the gastrointestinal tract, e.g. the gastric acidic content, the intestinal mucus layer or the enzymatic degradation, that they must surmount to reach their target. These limitations may be turned into opportunities through a rational design of lipid-based nanocarriers. For that purpose, this review focuses on the main challenges of the oral route indicating the strategies undertaken for lipid-based nanocarriers in order to overcome them. Understanding their shortcomings and identifying their strengths will determine the future clinical success of lipid-based nanocarriers.
Graphical abstract |
| doi_str_mv | 10.1007/s13346-021-00908-7 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7852471</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>33528830</sourcerecordid><originalsourceid>FETCH-LOGICAL-c446t-a8599655fd9154ea8ed60c3979ad4b4498877caf29814e6865460f2e8e5b80053</originalsourceid><addsrcrecordid>eNqNkU9LHTEUxUOpVHm-L-CizL5Mm0z-bwpl0FoQ3Ci4C5nMnWfkmQzJjMVv3zxHh3ZTzOYGcs7J4XcROiP4K8FYfsuEUiZq3JAaY41VLT-gk4ZoXFPN1Mf1Tu-O0TbnB1wOE0Rq-QkdU8obpSg-QeftnBKEqbLjmKJ195ArH6q9H31fdzZDXwUborMpeUi5GmKqYrL7qk_zruph758gPZ-io8HuM2xf5wbdXpzftJf11fXPX-2Pq9oxJqbaKq614HzoNeEMrIJeYEe11LZnHWNaKSmdHRqtCAOhBGcCDw0o4J3CmNMN-r7kjnP3CL0rxUsXMyb_aNOzidabf1-Cvze7-GSk4g2TpAQ0S4BLMecEw-ol2By4moWrKVzNC1cji-nz37-uljeKRfBlEfyGLg7ZeQgOVlkBLwgjRKrDDg4d1PvVrZ_s5GNo4xymYqWLNRd52EEyD3FOoSD_X_8_wKmkzg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Current approaches in lipid-based nanocarriers for oral drug delivery</title><source>MEDLINE</source><source>Web of Science - Science Citation Index Expanded - 2021<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" /></source><source>SpringerLink Journals - AutoHoldings</source><creator>Plaza-Oliver, María ; Santander-Ortega, Manuel Jesús ; Lozano, María Victoria</creator><creatorcontrib>Plaza-Oliver, María ; Santander-Ortega, Manuel Jesús ; Lozano, María Victoria</creatorcontrib><description>Lipid-based nanocarriers have gained much interest as carriers of drugs with poor oral bioavailability because of their remarkable advantages like low toxicity, affordable scale-up manufacture, strong biocompatibility or high drug loading efficiency. The potential of these nanocarriers lies in their ability to improve the gastrointestinal stability, solubility and permeability of their cargo drugs. However, achieving efficient oral drug delivery through lipid-based nanocarriers is a challenging task, since they encounter multiple physicochemical barriers along the gastrointestinal tract, e.g. the gastric acidic content, the intestinal mucus layer or the enzymatic degradation, that they must surmount to reach their target. These limitations may be turned into opportunities through a rational design of lipid-based nanocarriers. For that purpose, this review focuses on the main challenges of the oral route indicating the strategies undertaken for lipid-based nanocarriers in order to overcome them. Understanding their shortcomings and identifying their strengths will determine the future clinical success of lipid-based nanocarriers.
Graphical abstract</description><identifier>ISSN: 2190-393X</identifier><identifier>EISSN: 2190-3948</identifier><identifier>DOI: 10.1007/s13346-021-00908-7</identifier><identifier>PMID: 33528830</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject><![CDATA[Administration, Oral ; Biological Availability ; Biomedical and Life Sciences ; Biomedicine ; Drug Carriers ; Drug Delivery Systems ; Instruments & Instrumentation ; Life Sciences & Biomedicine ; Lipids ; Medicine, Research & Experimental ; Nanoparticles ; Original ; Original Article ; Pharmaceutical Sciences/Technology ; Pharmacology & Pharmacy ; Research & Experimental Medicine ; Science & Technology ; Technology]]></subject><ispartof>Drug delivery and translational research, 2021-04, Vol.11 (2), p.471-497</ispartof><rights>Controlled Release Society 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>true</woscitedreferencessubscribed><woscitedreferencescount>90</woscitedreferencescount><woscitedreferencesoriginalsourcerecordid>wos000614117800001</woscitedreferencesoriginalsourcerecordid><citedby>FETCH-LOGICAL-c446t-a8599655fd9154ea8ed60c3979ad4b4498877caf29814e6865460f2e8e5b80053</citedby><cites>FETCH-LOGICAL-c446t-a8599655fd9154ea8ed60c3979ad4b4498877caf29814e6865460f2e8e5b80053</cites><orcidid>0000-0001-7774-732X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s13346-021-00908-7$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s13346-021-00908-7$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>230,315,781,785,886,27929,27930,39263,41493,42562,51324</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33528830$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Plaza-Oliver, María</creatorcontrib><creatorcontrib>Santander-Ortega, Manuel Jesús</creatorcontrib><creatorcontrib>Lozano, María Victoria</creatorcontrib><title>Current approaches in lipid-based nanocarriers for oral drug delivery</title><title>Drug delivery and translational research</title><addtitle>Drug Deliv. and Transl. Res</addtitle><addtitle>DRUG DELIV TRANSL RE</addtitle><addtitle>Drug Deliv Transl Res</addtitle><description>Lipid-based nanocarriers have gained much interest as carriers of drugs with poor oral bioavailability because of their remarkable advantages like low toxicity, affordable scale-up manufacture, strong biocompatibility or high drug loading efficiency. The potential of these nanocarriers lies in their ability to improve the gastrointestinal stability, solubility and permeability of their cargo drugs. However, achieving efficient oral drug delivery through lipid-based nanocarriers is a challenging task, since they encounter multiple physicochemical barriers along the gastrointestinal tract, e.g. the gastric acidic content, the intestinal mucus layer or the enzymatic degradation, that they must surmount to reach their target. These limitations may be turned into opportunities through a rational design of lipid-based nanocarriers. For that purpose, this review focuses on the main challenges of the oral route indicating the strategies undertaken for lipid-based nanocarriers in order to overcome them. Understanding their shortcomings and identifying their strengths will determine the future clinical success of lipid-based nanocarriers.
Graphical abstract</description><subject>Administration, Oral</subject><subject>Biological Availability</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Drug Carriers</subject><subject>Drug Delivery Systems</subject><subject>Instruments & Instrumentation</subject><subject>Life Sciences & Biomedicine</subject><subject>Lipids</subject><subject>Medicine, Research & Experimental</subject><subject>Nanoparticles</subject><subject>Original</subject><subject>Original Article</subject><subject>Pharmaceutical Sciences/Technology</subject><subject>Pharmacology & Pharmacy</subject><subject>Research & Experimental Medicine</subject><subject>Science & Technology</subject><subject>Technology</subject><issn>2190-393X</issn><issn>2190-3948</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>HGBXW</sourceid><sourceid>EIF</sourceid><recordid>eNqNkU9LHTEUxUOpVHm-L-CizL5Mm0z-bwpl0FoQ3Ci4C5nMnWfkmQzJjMVv3zxHh3ZTzOYGcs7J4XcROiP4K8FYfsuEUiZq3JAaY41VLT-gk4ZoXFPN1Mf1Tu-O0TbnB1wOE0Rq-QkdU8obpSg-QeftnBKEqbLjmKJ195ArH6q9H31fdzZDXwUborMpeUi5GmKqYrL7qk_zruph758gPZ-io8HuM2xf5wbdXpzftJf11fXPX-2Pq9oxJqbaKq614HzoNeEMrIJeYEe11LZnHWNaKSmdHRqtCAOhBGcCDw0o4J3CmNMN-r7kjnP3CL0rxUsXMyb_aNOzidabf1-Cvze7-GSk4g2TpAQ0S4BLMecEw-ol2By4moWrKVzNC1cji-nz37-uljeKRfBlEfyGLg7ZeQgOVlkBLwgjRKrDDg4d1PvVrZ_s5GNo4xymYqWLNRd52EEyD3FOoSD_X_8_wKmkzg</recordid><startdate>20210401</startdate><enddate>20210401</enddate><creator>Plaza-Oliver, María</creator><creator>Santander-Ortega, Manuel Jesús</creator><creator>Lozano, María Victoria</creator><general>Springer US</general><general>Springer Nature</general><scope>95M</scope><scope>AFTVD</scope><scope>BLEPL</scope><scope>DTL</scope><scope>HGBXW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-7774-732X</orcidid></search><sort><creationdate>20210401</creationdate><title>Current approaches in lipid-based nanocarriers for oral drug delivery</title><author>Plaza-Oliver, María ; Santander-Ortega, Manuel Jesús ; Lozano, María Victoria</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c446t-a8599655fd9154ea8ed60c3979ad4b4498877caf29814e6865460f2e8e5b80053</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Administration, Oral</topic><topic>Biological Availability</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Drug Carriers</topic><topic>Drug Delivery Systems</topic><topic>Instruments & Instrumentation</topic><topic>Life Sciences & Biomedicine</topic><topic>Lipids</topic><topic>Medicine, Research & Experimental</topic><topic>Nanoparticles</topic><topic>Original</topic><topic>Original Article</topic><topic>Pharmaceutical Sciences/Technology</topic><topic>Pharmacology & Pharmacy</topic><topic>Research & Experimental Medicine</topic><topic>Science & Technology</topic><topic>Technology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Plaza-Oliver, María</creatorcontrib><creatorcontrib>Santander-Ortega, Manuel Jesús</creatorcontrib><creatorcontrib>Lozano, María Victoria</creatorcontrib><collection>Conference Proceedings Citation Index - Science (CPCI-S)</collection><collection>Conference Proceedings Citation Index - Science (CPCI-S) 2021</collection><collection>Web of Science Core Collection</collection><collection>Science Citation Index Expanded</collection><collection>Web of Science - Science Citation Index Expanded - 2021</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Drug delivery and translational research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Plaza-Oliver, María</au><au>Santander-Ortega, Manuel Jesús</au><au>Lozano, María Victoria</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Current approaches in lipid-based nanocarriers for oral drug delivery</atitle><jtitle>Drug delivery and translational research</jtitle><stitle>Drug Deliv. and Transl. Res</stitle><stitle>DRUG DELIV TRANSL RE</stitle><addtitle>Drug Deliv Transl Res</addtitle><date>2021-04-01</date><risdate>2021</risdate><volume>11</volume><issue>2</issue><spage>471</spage><epage>497</epage><pages>471-497</pages><issn>2190-393X</issn><eissn>2190-3948</eissn><abstract>Lipid-based nanocarriers have gained much interest as carriers of drugs with poor oral bioavailability because of their remarkable advantages like low toxicity, affordable scale-up manufacture, strong biocompatibility or high drug loading efficiency. The potential of these nanocarriers lies in their ability to improve the gastrointestinal stability, solubility and permeability of their cargo drugs. However, achieving efficient oral drug delivery through lipid-based nanocarriers is a challenging task, since they encounter multiple physicochemical barriers along the gastrointestinal tract, e.g. the gastric acidic content, the intestinal mucus layer or the enzymatic degradation, that they must surmount to reach their target. These limitations may be turned into opportunities through a rational design of lipid-based nanocarriers. For that purpose, this review focuses on the main challenges of the oral route indicating the strategies undertaken for lipid-based nanocarriers in order to overcome them. Understanding their shortcomings and identifying their strengths will determine the future clinical success of lipid-based nanocarriers.
Graphical abstract</abstract><cop>New York</cop><pub>Springer US</pub><pmid>33528830</pmid><doi>10.1007/s13346-021-00908-7</doi><tpages>27</tpages><orcidid>https://orcid.org/0000-0001-7774-732X</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2190-393X |
| ispartof | Drug delivery and translational research, 2021-04, Vol.11 (2), p.471-497 |
| issn | 2190-393X 2190-3948 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7852471 |
| source | MEDLINE; Web of Science - Science Citation Index Expanded - 2021<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" />; SpringerLink Journals - AutoHoldings |
| subjects | Administration, Oral Biological Availability Biomedical and Life Sciences Biomedicine Drug Carriers Drug Delivery Systems Instruments & Instrumentation Life Sciences & Biomedicine Lipids Medicine, Research & Experimental Nanoparticles Original Original Article Pharmaceutical Sciences/Technology Pharmacology & Pharmacy Research & Experimental Medicine Science & Technology Technology |
| title | Current approaches in lipid-based nanocarriers for oral drug delivery |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-11T09%3A22%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Current%20approaches%20in%20lipid-based%20nanocarriers%20for%20oral%20drug%20delivery&rft.jtitle=Drug%20delivery%20and%20translational%20research&rft.au=Plaza-Oliver,%20Mar%C3%ADa&rft.date=2021-04-01&rft.volume=11&rft.issue=2&rft.spage=471&rft.epage=497&rft.pages=471-497&rft.issn=2190-393X&rft.eissn=2190-3948&rft_id=info:doi/10.1007/s13346-021-00908-7&rft_dat=%3Cpubmed_cross%3E33528830%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/33528830&rfr_iscdi=true |